{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:17:38Z","timestamp":1759335458829,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.clinthera.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T23:44:20Z","timestamp":1518651860000},"page":"406-414.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus"],"prefix":"10.1016","volume":"40","author":[{"given":"James A.","family":"McKinnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby","family":"Corman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipen","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace H.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne M.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.01.010_bib1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.01.010_bib2","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2018.01.010_bib3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/678594","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus pneumonia in community hospitals","volume":"35","author":"Lewis","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2018.01.010_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2018.01.010_bib5","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2018.01.010_bib6","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.01.010_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.medmal.2013.09.011","article-title":"The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia","volume":"43","author":"Chavanet","year":"2013","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.clinthera.2018.01.010_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40121-015-0096-4","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with ceftaroline fosamil in a patient with inhalational thermal injury","volume":"4","author":"Faris","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clinthera.2018.01.010_bib9","doi-asserted-by":"crossref","first-page":"R118","DOI":"10.1186\/cc13914","article-title":"Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study","volume":"18","author":"Peyrani","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2018.01.010_bib10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1586\/14787210.2014.908118","article-title":"A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection","volume":"12","author":"Arshad","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"year":"2016","series-title":"VIBATIV\u00ae (telavancin), USP [package insert]","key":"10.1016\/j.clinthera.2018.01.010_bib11"},{"key":"10.1016\/j.clinthera.2018.01.010_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.01.010_bib13","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.01.010_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2018.01.010_bib15","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/cid\/civ536","article-title":"Telavancin hospital-acquired pneumonia trials: impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality","volume":"61","author":"Lacy","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.01.010_bib16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.clinthera.2014.06.029","article-title":"Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid","volume":"36","author":"Niederman","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.01.010_bib17","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/cc13996","article-title":"Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus","volume":"18","author":"Patel","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2018.01.010_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IPC.0000000000000372","article-title":"Ceftaroline fosamil for treatment of methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia and health care\u2013associated pneumonia: a 5-year matched case-control evaluation of epidemiology and outcomes","volume":"24","author":"Arshad","year":"2016","journal-title":"Infectious Dis Clin Prac"},{"key":"10.1016\/j.clinthera.2018.01.010_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2334-14-252","article-title":"Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment","volume":"14","author":"Minejima","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2018.01.010_bib20","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1378\/chest.128.3.1414","article-title":"Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia","volume":"128","author":"DeRyke","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2018.01.010_bib21","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2018.01.010_bib22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1097\/CCM.0b013e318183ef84","article-title":"Growth of intensive care unit resource use and its estimated cost in Medicare","volume":"36","author":"Milbrandt","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2018.01.010_bib23","unstructured":"Consumer Price Index https:\/\/www.bls.gov\/cpi\/#tables. Accessed April 5, 2017."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:35Z","timestamp":1758963035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818300122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0149291818300122"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.01.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}